The Baton Rouge Area Foundation announced Monday that it will move to a new location late this summer.  BRAF has outgrown its ...

Researchers have uncovered a stealth survival strategy that melanoma cells use to evade targeted therapy, offering a ...

It will take about four months to build out the 17,708-square-foot space; the foundation expects to move in during August.

Patients undergoing BRAF/MEK inhibitor therapy for melanoma more commonly experience VKH-like uveitis compared with other malignancy types.

Georgina V. Long, MD, MSc, discussed the long-term follow-up data for the combination of adjuvant dabrafenib and trametinib ...

To fight this, doctors often use drugs called BRAF inhibitors, such as vemurafenib, which can stop the cancer’s growth—at ...

FORE Biotherapeutics, a registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, today announced two plixorafenib abstracts have been ...

The BRAF mutation affects a small percentage of non-small cell lung cancer (NSCLC) cases, making the cancer more difficult to treat. In recent years, advances in treatment have helped to improve ...

Black Diamond Therapeutics has found a partner for its deprioritized solid tumor candidate. Five months after cutting support ...

No writing assistance was utilized in the production of this manuscript. BRAF, a member of a serine/threonine kinase protein family, serves as an immediate downstream effector of RAS in the MAPK ...

Around 1 in 2 melanoma patients will have mutations in the BRAF gene. This gene normally makes a protein which helps control cell growth, but mutations can cause the cells to grow and divide ...

We played a major role in characterising the BRAF gene and its role in cancer, increasing our understanding of malignant melanoma. Our work on the gene and the structure of the BRAF protein ...